Skip to main content
Watch Insiders

Corporate insider profile

Christopher Ryan Sullivan Insider Trades

Latest reported as Chief Financial Officer of Avalo Therapeutics, Inc. (AVTX).

Purchase filings
0
Reported companies
1
Net open-market value
-$3,452,444.58
Latest transaction
Sep 16, 2026

Affiliated corporations

Reported company relationships

AVTXLatest reported

Avalo Therapeutics, Inc.

Chief Financial Officer

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Sep 16, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale12,394$16.33$202,437
Sep 10, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale10,185$17.62$179,457
Aug 18, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale72,725$19.94$1,450,420
May 7, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale18,606$24.12$448,818
May 6, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale47,000$20.19$948,723
Apr 30, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale16,915$13.16$222,590